Compare SST & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SST | TXMD |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 25.9M |
| IPO Year | N/A | 2012 |
| Metric | SST | TXMD |
|---|---|---|
| Price | $2.72 | $2.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 8.2K | ★ 23.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.61 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $90.64 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.29 | $0.72 |
| 52 Week High | $11.30 | $2.95 |
| Indicator | SST | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 29.29 | 50.84 |
| Support Level | $0.34 | $2.07 |
| Resistance Level | $4.71 | $2.54 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 11.70 | 68.93 |
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.